首页> 外文期刊>Applied health economics and health policy >A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder
【24h】

A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder

机译:基于模型的双相情感障碍患者药物治疗经济评价的系统评价和系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background Bipolar disorder (BD) is a chronic and relapsing mental illness with a considerable health-related and economic burden. The primary goal of pharmacotherapeutics for BD is to improve patients' well-being. The use of decision-analytic models is key in assessing the added value of the pharmacotherapeutics aimed at treating the illness, but concerns have been expressed about the appropriateness of different modelling techniques and about the transparency in the reporting of economic evaluations.Objectives This paper aimed to identify and critically appraise published model-based economic evaluations of pharmacotherapeutics in BD patients. Methods A systematic review combining common terms for BD and economic evaluation was conducted in MED-LINE, EMBASE, PSYCINFO and ECONLIT. Studies identified were summarised and critically appraised in terms of the use of modelling technique, model structure and data sources. Considering the prognosis and management of BD, the possible benefits and limitations of each modelling technique are discussed. Results Fourteen studies were identified using model-based economic evaluations of pharmacotherapeutics in BD patients. Of these 14 studies, nine used Markov, three used discrete-event simulation (DES) and two used decision-tree models. Most of the studies "(n = 11) did not include the rationale for the choice of modelling technique undertaken. Half of the studies did not include the risk of mortality. Surprisingly, no study considered the risk of having a mixed bipolar episode.Conclusions This review identified various modelling issues that could potentially reduce the comparability of one pharmacotherapeutic intervention with another. Better use and reporting of the modelling techniques in the future studies are essential. DES modelling appears to be a flexible and comprehensive technique for evaluating the comparability of BD treatment options because of its greater flexibility of depicting the disease progression over time. However, depending on the research question, modelling techniques other than DES might also be appropriate in some cases.
机译:背景技术躁郁症(BD)是一种慢性且复发性的精神疾病,具有相当大的健康相关和经济负担。 BD的药物治疗的主要目标是改善患者的健康状况。决策分析模型的使用对于评估旨在治疗该疾病的药物治疗的附加价值至关重要,但人们对各种建模技术的适当性以及经济评估报告的透明度表示担忧。鉴定并严格评估已发表的基于模型的BD患者药物治疗的经济评价。方法在MED-LINE,EMBASE,PSYCINFO和ECONLIT中对BD的常用术语和经济评估进行了系统的综述。根据建模技术的使用,模型结构和数据源,对鉴定出的研究进行了总结和严格评估。考虑到BD的预后和管理,讨论了每种建模技术的可能的好处和局限性。结果使用基于模型的BD药物治疗经济学评估,确定了14项研究。在这14项研究中,有9项使用Markov,3项使用离散事件模拟(DES),而2项使用决策树模型。 “大多数研究(n = 11)均未包括选择建模技术的依据。一半的研究未包括死亡的风险。令人惊讶的是,没有研究考虑到混合性双相发作的风险。”这篇综述确定了各种建模问题,这些问题可能会降低一种药物治疗干预与另一种药物治疗的可比性,在未来的研究中更好地使用和报告建模技术至关重要,DES建模似乎是一种灵活而全面的技术,用于评估BD的可比性可以选择多种治疗方案,因为它具有更大的灵活性来描述疾病随时间的变化,但是,根据研究问题,在某些情况下,除DES以外的建模技术也可能适用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号